Serum Inflammatory Profile in Hereditary Transthyretin Amyloidosis: Mechanisms and Possible Therapeutic Implications
- PMID: 36552168
- PMCID: PMC9775257
- DOI: 10.3390/brainsci12121708
Serum Inflammatory Profile in Hereditary Transthyretin Amyloidosis: Mechanisms and Possible Therapeutic Implications
Abstract
Hereditary transthyretin (ATTRv) amyloidosis is a severe, progressive, and heterogeneous multisystemic condition due to mutations in the TTR gene. Although multiple aspects of its molecular pathophysiological mechanisms have been elucidated over the years, it is possible to hypothesize different pathogenetic pathways. Indeed, we extensively investigated the serum levels of several molecules involved in the immune response, in a cohort of ATTRv patients and healthy controls (HCs). Sixteen ATTRv patients and twenty-five HCs were included in the study. IFN-alpha levels were higher in ATTRv patients than in HCs, as well as IFN-gamma levels. By contrast, IL-7 levels were lower in ATTRv patients than in HCs. No significant difference between groups was found regarding IL-1Ra, IL-6, IL-2, IL-4, and IL-33 levels. Correlation analysis did not reveal any significant correlation between IFN-α, IFN-γ, IL-7, and demographic and clinical data. Larger and longitudinal studies using ultrasensitive methods to perform a full cytokine profiling are needed to better elucidate the role of inflammation in ATTRv pathogenesis and to test the reliability of these molecules as possible biomarkers in monitoring patients' progression.
Keywords: ATTRv; biomarker; degeneration; inflammation; therapy.
Conflict of interest statement
Marco Luigetti received financial grants (honoraria and speaking) from Ackea, Alnylam, Sobi, and Pfizer, and travel grants from Ackea, Alnylam, Sobi, Pfizer, Kedrion, and Grifols; Angela Romano received financial grants (honoraria and speaking) from Akcea, and travel grants from Akcea, Alnylam, Pfizer, and Csl Behring. Nicola De Stefano: Unrelated to this work, NDS is a consultant for Merck, Novartis, Sanofi Genzyme, Roche, and Bristol Myers Squibb and is on the speakers’ bureaus of Merck, Novartis, Roche, Sanofi Genzyme, Janssen and Bristol Myers Squibb. He has received travel funds from Merck, Novartis, Roche, Sanofi-Genzyme, and Teva and has grants pending from FISM. He is co-founder of Siena Imaging. Guido Primiano, Andrea Sabino, Valeria Guglielmino, Maria Ausilia Sciarrone, Francesca Vitali, Geny Piro, Carmine Carbone have no potential conflicts of interest to be disclosed. Domenico Plantone: Unrelated to this work, DP has received travel funds from Lilly and Novartis. Marco Luigetti, Angela Romano, and Guido Primiano are members of the European Reference Network for Neuromuscular Diseases—Project ID N° 870177.
Similar articles
-
Serum Biomarkers in Transthyretin Amyloidosis: An Overview of Neurofilaments, Cardiac, Renal, and Gastrointestinal Involvement.Neurol Ther. 2025 Feb;14(1):71-84. doi: 10.1007/s40120-024-00696-5. Epub 2025 Jan 3. Neurol Ther. 2025. PMID: 39754001 Free PMC article. Review.
-
Current Evidence Supporting the Role of Immune Response in ATTRv Amyloidosis.Cells. 2023 Sep 29;12(19):2383. doi: 10.3390/cells12192383. Cells. 2023. PMID: 37830598 Free PMC article. Review.
-
Inflammatory profiling of patients with familial amyloid polyneuropathy.BMC Neurol. 2019 Jun 28;19(1):146. doi: 10.1186/s12883-019-1369-4. BMC Neurol. 2019. PMID: 31253122 Free PMC article.
-
Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis.Front Mol Biosci. 2022 Mar 23;9:839917. doi: 10.3389/fmolb.2022.839917. eCollection 2022. Front Mol Biosci. 2022. PMID: 35402512 Free PMC article.
-
Plasma growth differentiation factor 15: a novel tool to detect early changes of hereditary transthyretin amyloidosis.ESC Heart Fail. 2021 Apr;8(2):1178-1185. doi: 10.1002/ehf2.13176. Epub 2020 Dec 30. ESC Heart Fail. 2021. PMID: 33381924 Free PMC article.
Cited by
-
Serum Biomarkers in Transthyretin Amyloidosis: An Overview of Neurofilaments, Cardiac, Renal, and Gastrointestinal Involvement.Neurol Ther. 2025 Feb;14(1):71-84. doi: 10.1007/s40120-024-00696-5. Epub 2025 Jan 3. Neurol Ther. 2025. PMID: 39754001 Free PMC article. Review.
-
Current Evidence Supporting the Role of Immune Response in ATTRv Amyloidosis.Cells. 2023 Sep 29;12(19):2383. doi: 10.3390/cells12192383. Cells. 2023. PMID: 37830598 Free PMC article. Review.
-
Biomarkers of axonal damage to favor early diagnosis in variant transthyretin amyloidosis (A-ATTRv).Sci Rep. 2024 Jan 5;14(1):581. doi: 10.1038/s41598-023-50212-2. Sci Rep. 2024. PMID: 38182630 Free PMC article.
-
Emerging multisystem biomarkers in hereditary transthyretin amyloidosis: a pilot study.Sci Rep. 2024 Aug 7;14(1):18281. doi: 10.1038/s41598-024-69123-x. Sci Rep. 2024. PMID: 39112608 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous